<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>MASH on AI 实战派 · 从技术到赚钱</title><link>https://guijiagi.com/tags/mash/</link><description>Recent content in MASH on AI 实战派 · 从技术到赚钱</description><generator>Hugo</generator><language>zh-cn</language><copyright>本站内容采用 CC BY-NC-SA 4.0 国际许可协议授权</copyright><lastBuildDate>Sun, 18 Oct 2026 10:54:00 +0800</lastBuildDate><atom:link href="https://guijiagi.com/tags/mash/index.xml" rel="self" type="application/rss+xml"/><item><title>阿斯利康 15 亿美元押注 Insitro 虚拟人平台，瞄准脂肪肝与心肌病新药靶点</title><link>https://guijiagi.com/posts/2026-10-18-19-astrazeneca-insitro-15b-virtual-human/</link><pubDate>Sun, 18 Oct 2026 10:54:00 +0800</pubDate><guid>https://guijiagi.com/posts/2026-10-18-19-astrazeneca-insitro-15b-virtual-human/</guid><description>10 月 15 日宣布的合作总额最高 15 亿美元，首付 4000 万，Insitro 用 AI 加实验室培养人体细胞研究 MASH 与心肌病，成功靶点后阿斯利康接管临床开发。</description></item></channel></rss>